Disease · MONDO_0001134

essential hypertension

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. essential hypertension. Diseases, record MONDO_0001134. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001134

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: essential hypertension; Open Targets
Open Targets ID: MONDO_0001134; Open Targets
Other names: idiopathic hypertension, primary hypertension; Open Targets
Disease Ontology: DOID:10825; Disease Ontology
MeSH: D000075222; MeSH
Orphanet: ORPHA:243761; Orphanet
Highest stage of its drugs: Approval, for 5 of its 84 drugs, from EMA Human Drugs and TTD; Open Targets

Drugs84

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
HYDROCHLOROTHIAZIDE	CHEMBL435	Small molecule	Approval	EMA Human Drugs	39	38	38	Drugs and targets
TELMISARTAN	CHEMBL1017	Small molecule	Approval	EMA Human Drugs	26	25	25	Drugs and targets
SPIRONOLACTONE	CHEMBL1393	Small molecule	Approval	EMA Human Drugs	4	3	3	Drugs and targets
MECAMYLAMINE	CHEMBL267936	Small molecule	Approval	TTD	1	0	0	Drugs and targets
SERACTIDE ACETATE	CHEMBL1201489	Protein	Approval	TTD	1	0	0	Drugs and targets
AMLODIPINE	CHEMBL1491	Small molecule	Phase 3	ClinicalTrials.gov	47	47	46	Drugs and targets
VALSARTAN	CHEMBL1069	Small molecule	Phase 3	ClinicalTrials.gov	24	24	24	Drugs and targets
ALISKIREN	CHEMBL1639	Small molecule	Phase 3	ClinicalTrials.gov	15	15	15	Drugs and targets
AZILSARTAN MEDOXOMIL	CHEMBL2028661	Small molecule	Phase 3	ClinicalTrials.gov	15	15	15	Drugs and targets
LOSARTAN	CHEMBL191	Small molecule	Phase 3	ClinicalTrials.gov	14	14	11	Drugs and targets

1 to 10 of 84

See all 84 drugs

Targets82

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
AGTR1	Type-1 angiotensin II receptor	14	Type-1 angiotensin II receptor antagonist	Approval	https://conductscience.org/library/genes/185	Drugs and targets
ACE	Angiotensin-converting enzyme	8	Angiotensin-converting enzyme inhibitor	Phase 3	https://conductscience.org/library/genes/1636	Drugs and targets
CACNA1C	Voltage-gated L-type calcium channel	8	Voltage-gated L-type calcium channel blocker	Phase 3	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated L-type calcium channel	8	Voltage-gated L-type calcium channel blocker	Phase 3	https://conductscience.org/library/genes/776	Drugs and targets
CACNA1F	Voltage-gated L-type calcium channel	8	Voltage-gated L-type calcium channel blocker	Phase 3	https://conductscience.org/library/genes/778	Drugs and targets
CACNA1S	Voltage-gated L-type calcium channel	8	Voltage-gated L-type calcium channel blocker	Phase 3	https://conductscience.org/library/genes/779	Drugs and targets
ADRB1	Adrenergic receptor beta	6	Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/153	Drugs and targets
NR3C2	Mineralocorticoid receptor	5	Mineralocorticoid receptor antagonist	Approval	https://conductscience.org/library/genes/4306	Drugs and targets
SLC12A3	Solute carrier family 12 member 3	4	Thiazide-sensitive sodium-chloride cotransporter inhibitor	Approval	https://conductscience.org/library/genes/6559	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	3	HMG-CoA reductase inhibitor	Phase 3	https://conductscience.org/library/genes/3156	Drugs and targets

1 to 10 of 82

See all 82 targets

Trials195

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00739973	Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension	Phase 3	2,694	2011-05-03	Hypertension	ALISKIREN, AMLODIPINE	Its record names the disease	ClinicalTrials.gov
NCT02603809	Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension	Phase 2	1,659	2020-04-13	Essential Hypertension	APROCITENTAN	Its record names the disease	ClinicalTrials.gov
NCT00529451	Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg	Phase 3	1,613	2011-03-25	Hypertension	ALISKIREN	Its record names the disease	ClinicalTrials.gov
NCT01785472	Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension	Phase 3	1,438	2015-09-04	Essential Hypertension	OLMESARTAN	Its record names the disease	ClinicalTrials.gov
NCT00696436	An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.	Phase 3	1,291	2011-04-19	Hypertension	AZILSARTAN MEDOXOMIL, OLMESARTAN, VALSARTAN	Its record names the disease	ClinicalTrials.gov
NCT00696241	Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension	Phase 3	1,275	2011-04-19	Hypertension	AZILSARTAN MEDOXOMIL, OLMESARTAN	Its record names the disease	ClinicalTrials.gov
NCT00437645	Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension	Phase 3	1,183	2011-02-14	Essential Hypertension	AMLODIPINE, VALSARTAN	Its record names the disease	ClinicalTrials.gov
NCT01599104	Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension	Phase 3	1,161	2015-08-06	Essential Hypertension	OLMESARTAN, SACUBITRIL, VALSARTAN	Its record names the disease	ClinicalTrials.gov
NCT00846365	Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension	Phase 3	1,085	2012-03-13	Essential Hypertension	AZILSARTAN MEDOXOMIL, CHLORTHALIDONE, OLMESARTAN MEDOXOMIL	Its record names the disease	ClinicalTrials.gov
NCT00699192	Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension	Phase 3	965	2011-06-06	Hypertension	AMLODIPINE, VALSARTAN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 195

See all 195 trials

Comparisons in its trials29

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Valsartan/Amlodipine 160/5 mg vs Amlodipine 10 mg: serious adverse events	11 of 592	8 of 591	1,183	NCT00437645	Trial comparisons
Azilsartan Medoxomil and Chlorthalidone vs Olmesartan Medoxomil and Hydrochlorothiazide: serious adverse events	24 of 418	26 of 419	837	NCT00996281	Trial comparisons
Losartan 50 mg/HCTZ 12.5 mg vs Valsartan 80 mg/HCTZ 12.5 mg: serious adverse events	11 of 425	5 of 383	808	NCT00546754	Trial comparisons
T80/A5 vs T80/A10: serious adverse events	1 of 501	1 of 232	733	NCT01134393	Trial comparisons
Azilsartan vs Amlodipine: serious adverse events	0 of 359	5 of 359	718	NCT01762501	Trial comparisons
Cohort 1 vs Cohort 2: serious adverse events	30 of 362	22 of 307	669	NCT00695955	Trial comparisons
Eprosartan vs Eprosartan Mesylate: serious adverse events	3 of 332	7 of 332	664	NCT01631227	Trial comparisons
Valsartan/Amlodipine 160/5 mg vs Valsartan 160 mg: serious adverse events	0 of 329	1 of 325	654	NCT01001572	Trial comparisons
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD vs Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD: serious adverse events	6 of 302	5 of 303	605	NCT00818883	Trial comparisons
Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination vs Amlodipine 5 mg Monotherapy: serious adverse events	1 of 269	2 of 262	531	NCT00558064	Trial comparisons

1 to 10 of 29

See all 29 comparisons in its trials

Papers from its trials76

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33649520	RESULT	1	PubMed
28441692	RESULT	1	PubMed
26829251	RESULT	1	PubMed
25716649	RESULT	1	PubMed
25271811	RESULT	2	PubMed
24990091	RESULT	1	PubMed
23932463	RESULT	1	PubMed
23344912	RESULT	1	PubMed
23205748	RESULT	1	PubMed
22608107	RESULT	3	PubMed

1 to 10 of 76

See all 76 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001134

GET https://conductscience.org/api/diseases/v1/MONDO_0001134/drugs?page=2

API reference For AI assistants